Literature DB >> 9514463

Aggressive lipid lowering in postcoronary angioplasty patients with elevated cholesterol (the Lovastatin Restenosis Trial).

S J Boccuzzi1, W S Weintraub, A S Kosinski, J B Roehm, J L Klein.   

Abstract

A substudy of the Lovastatin Restenosis Trial in patients with elevated cholesterol (>200 mg/dl) showed no evidence of an effect of aggressive lipid lowering on restenosis, confirming the results of the main trial.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9514463     DOI： 10.1016/s0002-9149(97)00980-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  2 in total

1.  Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice.

Authors:  E D Reis; M Roque; H Dansky; J T Fallon; J J Badimon; C Cordon-Cardo; S J Shiff; E A Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

2.  A promising carbon-11-labeled sphingosine-1-phosphate receptor 1-specific PET tracer for imaging vascular injury.

Authors:  Hongjun Jin; Hao Yang; Hui Liu; Yunxiao Zhang; Xiang Zhang; Adam J Rosenberg; Yongjian Liu; Suzanne E Lapi; Zhude Tu
Journal:  J Nucl Cardiol       Date:  2016-02-02       Impact factor: 5.952
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.